Fresh off a $3 million fundraise, Stratatech Corp. plans to begin Phase 2b clinical trials of its genetically engineered human-skin substitute.The Madison, Wis.-based company said it plans to begin the trials of its StrataGraft skin substitute, which is designed for patients suffering from burns or other sever wounds, in the second half of this year. [...]

Ending months of silence, Cellular Dynamics International Inc. is finally talking about its nearly $41 million fund-raise that it says makes it the highest-funded player in the stem cells industry.The company will use the $40.6 million infusion of capital to boost production of its stem-cell derived beating heart cells, the company’s first commercial product, which [...]

Stratatech Corp. has raised $3 million to continue developing a genetically engineered human skin substitute, according to a regulatory filing.The fundraise comes in the form of debt, options, warrants or other securities, the document filed with the Securities and Exchange Commission said. Robert Barnard, a company official, declined comment on the funding.The company’s lead product [...]

Radiopharmaceuticals company Cellectar Inc. has enrolled the last of eight patients in a Phase 1 trial of its cancer-treating drug candidate.The trial is designed to measure drug safety and dosimetry of Cellectar’s lead compound, called CLR1404. Dosimetry refers to the measurement of doses, which also allows investigators to understand how a drug will affect non-tumor [...]

Cellectar Inc. has raised $2.7 million for its radiopharmaceutical technology that treats and detects a variety of cancers, according to a regulatory filing. The company’s lead compound is currently in Phase 1 clinical trials for cancer treatment.